Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution . Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. PRODUCT MONOGRAPH. BYETTA® exenatide injection. µg/mL. mL prefilled pen (60 doses of 5 µg/dose) and. mL prefilled pen.

Author: Tonris Motaur
Country: Antigua & Barbuda
Language: English (Spanish)
Genre: Education
Published (Last): 25 January 2012
Pages: 367
PDF File Size: 2.27 Mb
ePub File Size: 2.50 Mb
ISBN: 252-1-83244-302-3
Downloads: 58288
Price: Free* [*Free Regsitration Required]
Uploader: Mikajas

Exenatide is cleared primarily by the kidney. The dosing of antidiabetic agents may require adjustment in patients who receive metoclopramide. If a dose is byteta, administer it as soon as noticed, as long as the next regularly scheduled dose is due at least 3 days later.

When carrying the pen away from home, store the pen at a temperature between 36 to 77 degrees F 2 to 25 degrees C and keep dry.

Bismuth Subsalicylate; Metronidazole; Tetracycline: Although specific dose recommendations are not available, a lower dose of the insulin or secretagogue may be required to reduce the risk of hypoglycemia in this setting. Rotate administration sites with each injection to prevent lipodystrophy.

For treatment of cold symptoms, nasal decongestants may be preferable for short term, limited use 1 to 3 days as an isert to systemic decongestants in patients taking medications for diabetes. Exenatide also slows gastric emptying thereby reducing the rate at which meal-derived glucose appears in the circulation.

Tobacco smoking is known to aggravate insulin resistance. The atypical antipsychotics have been associated with metabolic changes, paclage hyperglycemia, diabetic ketoacidosis, hyperosmolar, hyperglycemic states, and diabetic coma. Conversely, patients should be closely monitored for signs of hypoglycemia when therapy with a hydantoin is discontinued.

The hyperglycemic effect of diazoxide is expected to be antagonized by certain antidiabetic agents e.

Since clonidine inhibits the release of catecholamines, clonidine may hide symptoms of hypoglycemia such as tremor, tachycardia, and blood pressure changes.


Moderate Patients should be advised to limit alcohol ethanol ingestion when treated with an antidiabetic agent. Hypoglycemia has occurred during fluoxetine therapy.

Welcome to!

Patients treated inaert pasireotide may experience either hypoglycemia inesrt hyperglycemia. Blood glucose should be closely monitored and antidiabetic agents adjusted accordingly in this situation. Exenatide AUC increased proportionally over the therapeutic dose range of 5 to 10 mcg. Hypoglycemia, sometimes resulting in coma, can occur. AstraZeneca is not responsible for the privacy policy of any third-party websites. Extended-release exenatide must be injected immediately after suspended in the diluent within the Pen device or the syringe.

Patients receiving these drugs concomitantly with antidiabetic agents should be monitored packsge changes in glycemic control. Initially, 5 mcg subcutaneously twice daily given within the minute period before the morning and evening meal. See the manufacturer’s instructions for use for complete administration directions and illustrations. Alternatively, administer before the 2 main meals of the day, approximately 6 hours or more apart.

The manufacturer of digoxin recommends measuring serum digoxin concentrations prior to initiation of exenatide.

Official BYETTA® (exenatide) injection Healthcare Professional Website

Not a substitute for insulin and should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Staying Active Learn how regular physical pacckage can help you manage type 2 diabetes. Patients receiving this combination should be monitored for changes in glycemic control. Similar absorption is achieved with subcutaneous administration of exenatide in the abdomen, thigh, or arm.

Monitor blood glucose and glycemic control and adjust therapy as clinically indicated. Your email has been sent. Postmarketing reports of increased international normalized ratio INR sometimes associated with bleeding with concomitant use of warfarin. Moderate Monitor patients receiving octreotide concomitantly with insulin or other antidiabetic agents for changes in glycemic control and adjust doses of these medications accordingly.

Should not byetra used in patients with severe renal impairment or end-stage renal disease. Initially, surface-bound exenatide is released byettq in an initial peak around week 2. Because exenatide has a short elimination half-life and a high molecular weight, if it is excreted in human milk, it will probably be in low concentrations. An increased risk for hypoglycemia is possible. The effect of exenatide to slow gastric emptying may reduce the extent and rate of absorption of orally administered drugs.


When added to insulin detemir, a reduction in the dose of insulin detemir may be needed to reduce hypoglycemia; the insulin detemir package label recommends a dose of insulin detemir 10 units subcutaneously once daily when combining with a GLP-1 receptor agonist. Moderate Monitor blood glucose levels regularly in patients with diabetes, especially when pegvisomant treatment is initiated or when the dose is altered.

Paxkage hypokalemia may also lead to hyperglycemia. BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. Initiation with 5 mcg reduces the incidence and severity of gastrointestinal side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.

Subcutaneous dosage regular-release injection solution, Byetta. Possible mechanisms include atypical antipsychotic-induced insulin resistance or direct beta-cell inhibition.

Aminosalicylate sodium, Aminosalicylic acid: Patients with diabetes treated with pegvisomant and antidiabetic agents may be more likely to experience hypoglycemia. In addition, angiotensin II receptor antagonists have been associated with a reduced incidence in byetat development of new-onset diabetes in patients with hypertension or other cardiac disease.

Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any other antidiabetic packafe. Acetaminophen; Caffeine; Magnesium Byettta Phenyltoloxamine: It is unclear if hemoglobin A1C is improved or if improvements are sustained with continued treatment beyond 24 weeks.